Marks Group Wealth Management Inc Has $5.48 Million Stake in IQVIA Holdings Inc. $IQV

Marks Group Wealth Management Inc reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,107 shares of the medical research company’s stock after selling 8,888 shares during the period. Marks Group Wealth Management Inc’s holdings in IQVIA were worth $5,476,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the 4th quarter valued at approximately $25,000. Financial Freedom LLC acquired a new position in IQVIA during the 1st quarter worth approximately $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA during the 1st quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $27,000. Finally, Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $27,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on IQV shares. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Mizuho increased their price objective on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, HSBC reaffirmed a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $225.71.

IQVIA Price Performance

Shares of IQV opened at $207.31 on Thursday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company’s fifty day simple moving average is $183.85 and its 200 day simple moving average is $188.14. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04. The company has a market cap of $34.60 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 1.78 and a beta of 1.20.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the company posted $2.70 earnings per share. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a share repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.